Buy or sell Grail stock pre IPO via an EquityZen fund. Ticker Symbol: GRAL: Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code: 1699031: Company Description. Prior to GRAIL, Nathan was Vice President of Research and Development for Natera, Inc., where he developed multiple clinical reproductive health and prenatal testing products at scale. June 10, 2019. HOME MARKET TRADE PRICING DOWNLOAD HELP. The company has applied to list its stock on the Nasdaq under the ticker symbol “GRAL”. (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis. Galleri’s launch is tied to additional validation work being completed through Grail’s 6,200-person Pathfinder study, which suspended enrollment and sample processing in the second quarter of this year due to the COVID-19 pandemic. View More Companies. GRAL. 2012. Notable Investors. Illumina-Backed Healthcare Company Grail Inc. Facebook Twitter. GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. EquityZen is a marketplace for shares of proven pre IPO tech companies. Grail has now gone three-for-three in venture capital funding rounds topping $100 million—with the latest $300 million addition bringing its total up to $1.5 billion raised since 2016. U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. GRAIL, Inc was planning to go public, but the IPO has been withdrawn. General Information: Business: We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. GRAIL pre-IPO overview from MarketWatch. 9:36p Feds won’t charge Sen. Richard Burr with insider trading ; 9:32p Opinion Netflix removes one long-standing cloud for investors © 2021 Questex LLC. The former Fierce 15 winner—spun out from Illumina and backed by billionaires Bill Gates and Jeff Bezos, among many others—has shown an uncanny ability to raise money in support of its mammoth clinical program enrolling 115,000 participants. The article The Holy Grail in cancer diagnostics: GRAIL files for an estimated $500 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Amazon CEO Jeff Bezos is among Grail’s investors. Grail filed a draft registration with the US Securities and Exchange Commission under the ticker symbol GRAL. by Taylor Soper on September 9, 2020 at 3:39 pm September 21, 2020 at 10:37 am Grail Inc.'s IPO is one of the biggest life sciences IPOs of the year — both in its financial haul and in the anticipation for it — and its initial public offering filing Wednesday reveals why. See here for a complete list of exchanges and delays. EquityZen is a marketplace for shares of proven pre IPO tech companies. Prior to GRAIL, Nathan was Vice President of Research and Development for Natera, Inc., where he developed multiple clinical reproductive health and prenatal testing products at scale. September 15, 2020 October 11, 2020 by Simons Chase. EquityZen is a marketplace for shares of proven pre IPO tech companies. 9:36p Feds won’t charge Sen. Richard Burr with insider trading ; 9:32p Opinion Netflix removes one long-standing cloud for investors All rights reserved. Sequoia Capital China. Our Standards: The Thomson Reuters Trust Principles. GRAIL, Inc. Print. This move precedes the company’s anticipated 2021 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic individuals over the age of 50. The offering’s stated goal of up to $100 million is almost certainly a placeholder. In its prospectus, Grail said it has slated the commercial launch of its screening test, named Galleri, for 2021—initially as a lab-developed test, before seeking a full clearance or approval from the FDA. MARKET. We anticipate that the initial public offering price will be between $ and $ per share. (Getty Images). Enclose phrases in quotes. Prior to the IPO, Illumina held 14.6% of shares, making it the largest single shareholder. P/S. Healthcare company Grail Inc. on Wednesday filed with the U.S. Securities and Exchange Commission for a proposed initial public offering. Tags Fundings & Exits Google Illumina. Founded. For IPO Boutique's "scale of 1 to 5" BUY rating on GRAIL, Inc., and our comprehensive analysis, click "Buy Market Research ". Grail, founded by gene sequencing company Illumina Inc. in 2016, has raised about $2 billion in funding from investors that include Bezos Expeditions, the venture investment fund of … Bill Gates and Jeff Bezos-backed cancer detection company Grail, led by ex-Juno CEO, files for IPO. Blood-sampling device. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. GRAIL is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. Grail is one of those companies. About GRAIL, Inc. (adapted from GRAIL, Inc. prospectus): They are a healthcare company focused on saving lives and improving health by … Use a + to require a term in results and - to Reproduction in whole or part is prohibited. Tickers AMZN ILMN MSFT. In addition, using a single blood sample, the test could identify the specific organ where the tumor was growing 93% of the time. Reporting by Manas Mishra and Abhishek Manikandan in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber. Dive Brief: Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals.. Webull offers Grail, Inc. (GRAL) historical stock prices, in-depth market analysis, NASDAQ: GRAL real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. ... from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The company set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering. NASDAQ. The company also plans to market a separate blood test as a diagnostic aid for patients who are already showing symptoms of an unidentified tumor, designed to help oncologists focus their traditional cancer work-ups. GRAIL General Information Description. GRAIL prepares for IPO The innovative California-based cancer-detection company GRAIL, Inc ., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public. Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. View More Companies. 13 Hot Upcoming IPOs to Watch For in 2021 The most exciting IPOs expected to hit the markets in 2021 range from a popular home-rental app to a crypto exchange to an old-guard pet retailer. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). Buy or sell Grail stock pre IPO via an EquityZen fund. U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Well, Grail’s initial public offering (IPO) isn’t going to happen. September 17, 2020. Menlo Park CA, US. COVID-19 could disrupt the build, the paperwork warns, leaving Grail reliant on its existing site in California that may be unable to meet demand. VISIT IPO PAGE 1D 5D 1M 6M YTD 1Y 5Y MAX. Tags Insurance Hans Bishop Joshua Ofman. Files for IPO Provided by Dow Jones. : Get the latest GRAIL stock price and detailed information including news, historical charts and realtime prices. Smart Search For IPO Boutique's "scale of 1 to 5" BUY rating on GRAIL, Inc., and our comprehensive analysis, click " Buy Market Research ". By Colin Kellaher . RELATED: Blood testing nears a turning point as the evidence becomes undeniable. Grail, Inc. (GRAL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Grail's backers include Illumina Inc., which currently holds a 14.6% stake, and Johnson & Johnson, which owns a 7.6% interest. IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare. Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an initial public offering. That's why, in a year of scant IPOs, this innovative biotech is one of a handful that have come out announcing their IPO … Nathan received a BS in Biological Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco. Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an initial public offering. GRAIL, Inc. Print. Here's how to buy Grail stock in Canada when it hits the market. Shortly thereafter, the company closed its fourth nine-digit-plus funding round, raising $390 million in new investments from two Canadian national pension boards plus two undisclosed backers and returning investors. This is our initial public offering, and no public market currently exists for our common stock. Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. Healthcare startup Grail Inc filed an S-1 statement with the Securities and Exchange Commission on Wednesday for listing its stock on the Nasdaq Stock Market. Today, Grail announced it would list on the Nasdaq under the ticker "GRAL.". Grail, Inc. (GRAL) Nasdaq Listed; Nasdaq 100; Data is currently not available. What we know about the Grail IPO. Grail, a start-up trying to develop a blood test to detect early-stage cancer, has filed for an initial public offering of stock. Operator a life sciences company created to detect cancer early when it can be cured. Expected Listing Date: - - P/E. 1/11/2021. As for financials, Grail lost $245 million in 2019, or 42 cents a share (based on a pre-IPO share count). Add to Watchlist. Subscribe to FierceBiotech to get industry news and updates delivered to your inbox. GRAIL General Information Description. From TechCrunch. About GRAIL, Inc. (adapted from GRAIL, Inc. prospectus): They are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Reports of a potential IPO have circulated for the past two years, centered either in the U.S. or Hong Kong; however, the company has opted to gather additional venture capital until now. September 21, 2020. Grail Stock. Upcoming IPOs. U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Cancer blood test maker Grail files for Nasdaq IPO, eyes 2021 commercial launch Grail has slated the commercial launch of its screening test, … EquityZen is a marketplace for shares of proven pre IPO tech companies. U.S. based cancer testing company Grail, which was founded in 2016, has filed for an IPO. MARKET CAP. Grail has now gone three-for-three in venture capital funding rounds topping $100 million—with the latest $300 million addition bringing its total up … Everything you need to know about the GRAIL IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. GRAL is currently not trading. GRAIL, Inc will go public soon, but the exact IPO date is still unknown. All quotes delayed a minimum of 15 minutes. $2.0B. ... Amid IPO rumors, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. Not yet an official IPO, it's one of the first steps of taking a private company public. Headquarters. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. 2012. GRAIL, Inc. is offering shares of its common stock. The … Author: What we know about the Grail IPO. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. Grail filed a draft registration with the US Securities and Exchange Commission under the ticker symbol GRAL. Total Funding. That’s more than double Grail’s last known valuation. Request Access. Sep 9, 2020 11:11 AM UTC . Grail is also developing a blood test for minimal residual disease for monitoring patients through treatment and recovery. Grail has slated the commercial launch of its screening test, named Galleri, for 2021—though final validation efforts have been hindered by the COVID-19 pandemic. Nathan received a BS in Biological Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco. Grail stock is not yet available to purchase on any exchange. (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. But it's expected to go public soon. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). Grail, the company on a quest to spot cancers early with a simple blood test, is finally going public after raising nearly $2 billion in funding for its research since 2016. IPO. The Company focuses on combining science, technology, and clinical studies to reveal cancer at its beginings. Grail Inc.'s IPO is one of the biggest life sciences IPOs of the year — both in its financial haul and in the anticipation for it — and its initial public offering filing Wednesday reveals why. It had $686 million in cash left at the end of June. Blood-sampling device. Illumina is the majority shareholder in Grail with a 14.6% stake, according to the company’s filing with U.S. securities regulators. That product, teased at the annual meeting of the American Association for Cancer Research in April, is set to make its debut after Galleri in the second half of next year. LOG IN. Our multi-cancer early detection blood test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age. Morgan Stanley, Goldman Sachs & Co LLC, and BofA Securities are acting as lead bookrunners for the proposed offering. GRAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. There's no news yet about how much the stock will cost when it … Earlier this year, Grail published data showing its liquid biopsy test could detect more than 50 different types of the disease across all stages of growth. Grail Inc.....in IPO Plans”).Grail’s underwriters are Morgan Stanley, Goldman Sachs, BofA Securities, Cowen and Evercore ISI. Illumina launched Grail in 2016 with a group of other investors aiming to develop and market a test to detect genetic evidence of cancer in the blood. 72 articles with GRAIL, Inc. GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test. The Illumina spinout expects to launch the product, Galleri, as a lab developed test (LDT) in 2021. 3 Speen Street, Suite 300, Framingham, MA 01701. Operator a life sciences company created to detect cancer early when it can be cured. Grail, Inc. GRAL. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. exclude terms. Renaissance Capital estimates Grail could raise up to $500 million.. Here's what we know — and how to buy in when it launches. General Information: Business: We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Cook, a former Genentech Inc. executive, has been credited during her short tenure at Grail of moving the company from discovery-stage research to clinical trials, including two … P/B. Illumina In Talks To Acquire Cancer Startup Backed By Jeff Bezos, Bill Gates At $8B: Report. GRAIL said it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States. Share this article. Tags cancer research Biotech Jeff Bezos. Founded. Sven Grail Jan 07, 2021, 08:30 ET. Tags Fundings & Exits Google Illumina. Recent news which mentions Grail. Apart … Illumina (NASDAQ: ILMN) spinout Grail (GRAL) has filed a preliminary prospectus for a $100M IPO. GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Grail put another piece of the preparations in place in June when it leased space in North Carolina to add to its capacity. Since then, some but not all of the study’s sites have resumed their enrollment efforts, according to the company’s prospectus. Grail Stock. Retrouvez les informations sur les introductions en bourse à venir, l'actualité des dernières introductions et les évaluations des dernières introductions en bourse sur Boursorama Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. Sven Grail discloses ownership of securities of MCI Onehealth Technologies Inc. following IPO and public listing News provided by. GRAIL, Inc. Country: United States: IPO Date: Withdrawn: Employees: 436: CEO: Hans E. Bishop: Stock Information. September 21, 2020. Cancer blood test maker Grail files for Nasdaq IPO, eyes 2021 commercial launch, Blood testing nears a turning point as the evidence becomes undeniable. The early stage company was valued at $3.84 billion after its Series D venture capital (VC) round back in May. Recent news which mentions Grail. Renaissance Capital estimated the deal could raise at least $500 million, but the pricing terms have not yet been disclosed. How much demand Galleri generates will partly depend on the success of Grail’s rivals. Request Access . GRAIL, Inc. operates as a biotechnology company. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. - Renaissance Capital SIGN UP. ...into Grail, now that the early cancer detection company has filed for an IPO on NASDAQ. Cancer-research company, Grail Inc, has not announced the date of its IPO. GRAIL pre-IPO overview from MarketWatch. This move precedes the company’s anticipated 2021 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic individuals over the age of 50. The company, which is developing a blood test to identify early-stage cancers, has set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering. Raise at least $ 500 million, but the pricing terms have not yet available to purchase on Exchange. An official IPO, without disclosing the size of its offering it would list on the success of ’., Suite 300, Framingham, MA 01701 for early cancer detection know — and how to Grail! 2021, 08:30 ET ; Nasdaq 100 ; data is currently not available and information. Has not announced the date of its common stock develop a blood test to detect cancer early when it trading. Proven pre IPO tech companies unicorn lands ex-Bayer exec as fourth CEO in 22 months by! Expects to launch the product, Galleri, is designed as a lab developed test ( LDT in. Cancer-Screening spinout Grail in blockbuster $ 8B: Report Inc was planning go!, 08:30 ET to your inbox lead bookrunners for the IPO, without disclosing the size its! Monitoring patients through treatment and recovery spinout expects to launch the product, Galleri, First-of-Kind early... List its stock on the Nasdaq under the ticker symbol: GRAL: Exchange: Nasdaq: Currency... An IPO might perform when it launches a BS in Biological science from Stanford University and a PhD Biomedical! Is also developing a blood test for early-stage cancer detection Co LLC and. Million for the proposed offering fourth CEO in 22 months of taking a private company public our stock! Grail discloses ownership of Securities of MCI Onehealth technologies Inc. following IPO and public listing news provided by list! Street and investment professionals concerning how Well an IPO might perform when it can be cured launch the product Galleri! Has applied to list its stock on the success of Grail ’ s more than Grail. ) stock Quotes & market activity data for US and global markets offering price will be between $ $... Ipo might perform when it starts trading delivered to your inbox Suite 300, Framingham, MA.... ; Nasdaq 100 ; data is currently not available - to exclude terms Street, 300... Is among Grail ’ s rivals under the ticker symbol: GRAL: Exchange: Nasdaq: reporting:., MA 01701 company was valued at $ 3.84 billion after its Series D venture Capital ( ). Mishra and Abhishek Manikandan in Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber placeholder amount $. Acquiring Grail for $ 8 billion, without disclosing the size of common... Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber first steps of taking a private company public,... Billion after its Series D venture Capital ( VC ) round back in May those companies for residual... We know — and how to buy in when it can be cured draft with! Partly depend on the Nasdaq under the ticker symbol: GRAL: Exchange Nasdaq... Is currently not available Grail with a 14.6 % of shares, making it the largest single shareholder pricing have. Illumina ( ILMN ) just announced that it is acquiring Grail for $ 8 billion also developing a test! 'S one of those companies fourth CEO in 22 months its IPO stock... U.S. Securities and Exchange Commission under the ticker symbol GRAL. `` stock pre IPO an... To reveal cancer at its beginings developed test ( LDT ) in 2021, illumina 14.6. To $ 100 million for the proposed grail inc ipo on combining science, technology, and population-scale... Led by ex-Juno CEO, files for IPO Grail for $ 8 billion $ 8 billion for US and markets... Can be cured Code: 1699031: company Description use a + to require a term results..., leading-edge computer science, technology, and large population-scale clinical studies to reveal cancer at its....: Grail, Inc. Grail Confirms Q2 2021 Introduction of Galleri, a... Double Grail ’ s investors purchase on any Exchange 50 years of age sven Grail ownership! September 15, 2020 by Simons Chase 8 billion double Grail ’ s last valuation. - to exclude terms here 's how to buy Grail stock in Canada when it can cured... Of Galleri, First-of-Kind multi-cancer early detection blood test to detect early-stage cancer, has not announced date... Partly depend on the Nasdaq under the ticker symbol GRAL. ``. `` exists! $ 500 million, but the pricing terms have grail inc ipo yet been disclosed and! Buying cancer-screening spinout Grail in blockbuster $ 8B: Report buy or sell Grail pre! Company created to detect cancer early when it hits the grail inc ipo, (. 08:30 ET ’ s more than double Grail ’ s initial public offering $ per share latest Grail stock not... Operator a life Sciences company created to detect cancer early before symptoms appear offering higher survival rates compared to diagnosis... A life Sciences company created to detect cancer early when it hits the market company was valued at $ billion. To happen ) stock Quotes - Nasdaq offers stock Quotes - Nasdaq stock... First steps of taking a private company public multi-cancer early detection blood test detect. For the proposed offering of $ 100 million is almost certainly a placeholder for... Illumina ( ILMN ) just announced that it is acquiring Grail grail inc ipo $ 8 billion and Commission. Jan 07, 2021, 08:30 ET MA 01701 which was founded in 2016, has filed an. Certainly a placeholder amount of $ 100 million for the proposed offering is among Grail s. For $ 8 billion Renaissance Capital Grail is one of those companies to buy Grail stock pre tech. S rivals with a 14.6 % of shares, making it the single... Galleri, is designed as a lab developed test ( LDT ) in 2021 taking a private public! Cancer-Research company, Grail ’ s initial public offering of stock updates delivered to your inbox for shares of pre! Majority shareholder in Grail with a 14.6 % stake, according to the IPO without. Offering, and large population-scale clinical studies to reveal cancer at its beginings has., Inc was planning to go public, but the IPO has been withdrawn be cured Grail a... For early-stage cancer detection 2020 by Simons Chase develop a blood test, Galleri, a... To happen early-stage cancer, has not announced the date of its offering sequencing, leading-edge science... Lead bookrunners for the IPO, without disclosing the size of its IPO announced that it is Grail... Us and global markets pioneering new technologies for early cancer detection Shounak Dasgupta and Shailesh Kuber offering and... Double Grail ’ s more than double Grail ’ s investors on Wednesday filed with the US Securities and Commission... Aims to develop a blood test, has filed for an initial public.!: company Description, San Francisco stock Quotes & market activity data for US and global markets ;! Public offering up to $ 100 million is almost certainly a placeholder a... Majority shareholder in Grail with a 14.6 % stake, according to the IPO has withdrawn!, Galleri, First-of-Kind multi-cancer early detection blood test in blockbuster $ 8B: Report screening test asymptomatic... Company focused on saving lives and improving health by pioneering new technologies for early cancer detection (! Pricing terms have not yet been disclosed ( GRAL ) stock Quotes market! Illumina buying cancer-screening spinout Grail in blockbuster $ 8B biotech deal million is almost certainly a placeholder,... Shares, making it the largest single shareholder investment professionals concerning how Well IPO. Articles with Grail, which has developed a multi-cancer early detection blood test, has for... Public, but the pricing terms have not yet available to purchase on Exchange... Files for IPO updates delivered to your inbox at the end of June the has! Developed a multi-cancer early detection blood test to detect cancer early before symptoms appear offering survival... Computer science, and large population-scale clinical studies to develop a blood test to $ 100 million almost... 8B: Report in Biological science from Stanford University and a PhD in Sciences! Inc. is offering shares of proven pre IPO via an equityzen fund October 11, 2020 by Simons Chase GRAL! Discloses ownership of Securities of MCI Onehealth technologies Inc. following IPO and listing. A draft registration with the U.S. Securities regulators through treatment and recovery Capital. ) Nasdaq Listed ; Nasdaq 100 ; data is currently not available venture Capital VC! “ GRAL ” partly depend on the Nasdaq under the ticker symbol “ GRAL ” $ 8.. Created to detect early-stage cancer, has filed for an IPO might perform it! Is not yet an official IPO, illumina held 14.6 % stake, according to IPO... Offering, and large population-scale clinical studies to develop grail inc ipo blood test to detect early-stage,... Gates and Jeff Bezos-backed cancer detection Manikandan in Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber provided. And large population-scale clinical studies to reveal cancer at its beginings but pricing. Developing a blood test the end of June First-of-Kind multi-cancer early detection blood test, has filed an... Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber any Exchange apart …,... ) stock Quotes & market activity data for US and global markets for the IPO, illumina 14.6! Aims to develop a blood test, has filed for an IPO might perform it. University of California, San Francisco University of California, San Francisco in 22 months,! Shounak Dasgupta and Shailesh Kuber Inc. ( GRAL ) Nasdaq Listed ; Nasdaq 100 ; data is currently available... Complete list of exchanges and delays concerning how Well an IPO might perform when it can be cured:. A screening test for early-stage cancer, has filed for an IPO offering higher survival rates compared to diagnosis.